Vitamin D and Age-Related Macular Degeneration by Hemphill, Mandy
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2017
Vitamin D and Age-Related Macular Degeneration
Mandy Hemphill
Walden University
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.
  
   



















has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  




Dr. Hadi Danawi, Committee Chairperson, Public Health Faculty 
Dr. Aimee Ferraro, Committee Member, Public Health Faculty 






Chief Academic Officer 















BS, Southern Methodist University, 1996 
 
 
Dissertation Submitted in Partial Fulfillment of the  
Requirements for the Degree of  




Walden University  
February 2017 
Abstract 
Age-related macular degeneration (AMD) is the leading cause of vision loss in 
individuals aged 50 years and older and is estimated to affect as many as 11 million 
individuals in the United States. The purpose of this study was to examine the association 
between vitamin D and AMD disease progression. The life course epidemiology 
framework model was used to explore how vitamin D level as a risk factor may have an 
association to AMD disease through time. Data in the 2005–2008 National Health and 
Nutrition Examination Survey (NHANES) database were collected on vitamin D levels 
and identified stages of AMD level based on graded fundus eye exams from an available 
sample size of 5,604 participants. A quantitative cross-sectional study approach was used 
to address this gap in knowledge. A bivariate analysis was used to examine each 
independent variable (age, race/ethnicity, smoking status, and diabetes) to the dependent 
variable AMD from the 2005–2008 NHANES dataset. A multivariate logistic regression 
analysis was performed with AMD including each independent variable found to be 
significant. The findings from this study failed to suggest an association between vitamin 
D levels to AMD, with or without the covariates included in the model. There was not an 
association found between vitamin D level and presence of AMD. An association was 
found between age, smoking, and race to presence of AMD in each of the bivariate 
models. The findings from this study could be used for positive social change by 
encouraging medical and public health agencies to target screening programs at high-risk 
age, smoking, and race groups. There remains to be conflicting data in the literature. This 
study adds to the body of literature suggesting that higher levels of vitamin D are not 
necessarily beneficial as they pertains to AMD. 
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Chapter 1: Introduction to the Study  
Introduction 
As the term implies, age-related macular degeneration (AMD) refers to macular 
degeneration that occurs with age without any other precipitating conclusive associative 
risk factors in individuals aged 50 years and older (National Eye Institute [NEI], 2015). 
AMD is an ophthalmic condition leading to gradual loss of vision that may not cause 
noticeable symptoms in the early stages of the disease. However, through time, blurring 
of vision, and loss of sharpness in vision can occur. AMD can result in a wide range of 
vision-related symptoms causing impairment that include blurriness, decreased central 
vision, distortion of images and lines, decreased intensity or brightness of colors, reduced 
night vision, glare or scotoma (blind spot) (NEI, 2015).  
Should modifiable factors that are related to AMD development or disease 
progression be identified, then there is a potential to have a positive effect on predicted 
growing numbers. In Chapter 1, I discuss a review of the existing literature on the topic 
of the association of vitamin D levels to AMD and why this association needs to be 
explored further. In addition, the research questions and hypotheses that are examined are 
stated along with the theoretical framework that was used for the study, discussion of the 
nature of the study, assumptions, limitations, terms used in the study are defined, and, 





Several studies have evaluated vitamin D levels and its association with AMD. 
Parekh et al. (2007) provided information suggesting that vitamin D might have a 
protective effect against AMD. However, Cougnard-Gregoire et al. (2015) found 
contradicting results in a population-based sample of French older subjects from a 
community dwelling that did not find a specific role for vitamin D in AMD. One notable 
difference between these studies was that the former included 7,752 individuals in their 
study population compared to 697 subjects in the latter (Parekh, 2007; Cougnard-
Gregoire, 2015).  
Millen and colleagues (2015) conducted a study that found that vitamin D 
deficiency was associated to AMD, with the highest risk in individuals that also 
contained 2 risk alleles for complement factor H (CFH) and complement factor I (CFI) 
genotypes. Variants in these genes have been shown to be associated with increased 
AMD risk – for both early- and late-stage disease (Edwards et al., 2005). The recent 
study conducted by Millen and colleagues (2015) suggested there was a joint effect with 
vitamin D level and genotypes of known high genetic risk to AMD. 
Itty and colleagues (2014) provided information that compared 25-
hydroxyvitamin D (25OHD) levels in subjects with different forms of AMD 
demonstrating lower levels of 25OHD in neovascular AMD (NVAMD), an advanced 
form, suggesting vitamin D could be a modifiable risk factor. Kim, Han, and Jee (2014) 
conducted a study that concluded that high serum levels of vitamin D were inversely 




from the one by Parekh and colleagues (2007) in that the latter found serum vitamin D 
levels to demonstrate a relationship or association with early AMD, but not in the 
advanced form of AMD.  
Several studies have evaluated the association between vitamin D levels and 
AMD. Of the few studies that have been done, conflicting results have suggested that it is 
difficult to draw definitive conclusions based on what is currently known. The 
association between vitamin D to AMD still remains unclear and the small number of 
studies conducted suggests that this specific association warrants further study. 
AMD is a disease of the retina, or back of the eye, that, if left untreated, can lead 
to blindness. AMD is classified by four stages: no AMD, early AMD, intermediate AMD, 
or late AMD (Van Lookeren Campagne, LeCouter, Yaspan, & Ye, 2014). There are two 
types of late stage AMD: NVAMD (often referred to as wet AMD) and geographic 
atrophy (GA; often referred to as dry AMD) (Van Lookeren Campagne et al., 2014; 
Ferris et al., 2013).  
Few recognized phenotypes exist for AMD. AMD fundus photos are imaging 
pictures that are taken of the retina (the back part of the eye) in a doctor’s office to 
identify and diagnose the disease (Bird et al., 1995). Classification of the photos using 
different grading systems can result in patients that demonstrate a phenotype that falls in 
a category that is specific to the disease (NEI, n.d.). AMD patients will often demonstrate 





Vitamin D (25OHD) is a fat-soluble vitamin that can be found in some foods and 
is broken down by ultraviolet light (National Institutes of Health Office of Dietary 
Supplements, 2015). Vitamin D has been shown to play multiple roles in human health 
including its anti-inflammatory effects and that it is also an immune-modulator (Golan, 
Shalev, Treister, Chodick, & Loewenstein, 2011; Manolagas, Provvedini, Murry, 
Tsoukas, & Deftos, 1986). Calcitriol is the active hormonal form of vitamin D and has 
been demonstrated to affect endothelial cells (Albert et al., 2007). Proteins for the vitamin 
D receptor and the enzyme that converts the major circulating metabolites of vitamin D to 
its active hormone, calcitriol, are expressed in the retina (Zampatti et al., 2014). Albert 
and colleagues (2007) utilized a mouse model to demonstrate that calcitriol was a potent 
inhibitor of retinal neovascularization. Their data suggested that calcitriol might provide 
benefits in patients with neovascular eye diseases (Albert et al., 2007). 
Vitamin D deficiency may increase the risk for developing AMD (Itty et al., 
2014; Parekh et al., 2007). Few studies have examined the association of vitamin D levels 
and AMD. Parekh and colleagues (2007) conducted a study using the National Health 
and Nutrition Examination Survey (NHANES) data from 1988 through 1994 and found 
levels of vitamin D to be inversely associated with early AMD, but not advanced AMD, 
suggesting the vitamin may provide a protective role for the disease. Since then, several 
studies have shown an association of AMD with vitamin D (Millen et al., 2015; Itty et al., 
2014; Kim et al., 2014;). However, several studies have not found an association 
(Cougnard-Gregoire et al., 2015; Park et al., 2014). Study design and data collection 




example, data collection methods and samples were taken primarily from a Korean 
population in the Park and colleagues (2014) study.  
Statement of the Problem 
Current global estimates indicate that 30–50 million people have AMD (Birch & 
Liang, 2007). Those numbers are projected to rise to 288 million by the year 2040 
(Wong, 2014). AMD is the leading cause of severe and irreversible vision loss in the 
developed world in people older than 50 years and continues to grow as a public health 
problem (Wong, 2014). It is critical to continue to attempt to understand factors that 
affect the development of the disease or potentially advance disease progression. 
Conflicting results from the limited number of studies on the association of vitamin D 
and AMD suggest a gap in the literature and justification that further investigation is 
warranted. Additional research on the association of vitamin D and AMD may provide 
more information that will assist in awareness and understanding of factors related to the 
disease. Identifying factors that could be easily modified has the potential to positively 
affect the growing public health burden. 
Purpose of the Study 
The purpose of this study was to examine the association between vitamin D and 
AMD. I used a quantitative cross-sectional approach to address this gap in knowledge. I 
also used a logistic regression statistical methods analysis to examine data in the 
NHANES database that was collected by examiners on vitamin D and identified stages of 




stages of AMD disease across participants attempting to explore whether an association 
existed.  
The independent variable in the study was level of vitamin D. The dependent 
variable was stage of AMD. The covariates were diabetes, age, race, and smoking status.  
Research Questions and Hypotheses 
The following research questions and hypotheses have been derived from a 
review of existing literature on the topic of vitamin D level and its association with 
AMD. 
RQ1: What is the association between vitamin D level (high versus low) and the 
development of AMD? 
H01: There is no association between vitamin D level (high versus low) and the 
development of AMD. 
Ha1: There is an association between vitamin D level and the development of 
AMD. 
RQ2: What is the association between diabetes (yes/no) and development of 
AMD? 
H02: There is no association between diabetes (yes/no) and the development of 
AMD. 
Ha2: There is an association between diabetes (yes/no) and the development of 
AMD. 
RQ3: What is the association between age and development of AMD? 




Ha3: There is an association between age and the development of AMD. 
RQ4: What is the association between race and the development of AMD? 
H04: There is no association between race and the development of AMD. 
Ha4: There is an association between race and the development of AMD. 
RQ5: What is the association between smoking (yes/no) and the development of 
AMD? 
H05: There is no association between smoking (yes/no) and the development of 
AMD. 
Ha5: There is an association between smoking (yes/no) and the development of 
AMD. 
RQ6: What is the association between vitamin D level and the development of 
AMD, after controlling for covariates? 
H06: There is no association between vitamin D level and the development of 
AMD after controlling for covariates. 
Ha6: There is an association between vitamin D level and the development of 
AMD after controlling for covariates. 
I analyzed the first five questions using binary logistic regression with a binary 
outcome AMD (yes = 1 and no = 0). I analyzed the final (sixth) question using a 
multivariate model. Logistic regression modeling was used to develop the most 





Theoretical Framework for the Study  
The theoretical base for this study was the life course epidemiology model. 
According to Parekh and Zizza (2013), the life course theory when applied in 
epidemiology can provide a framework that will examine how nutrition along with other 
risk factors can have a long-term effect on chronic disease development. This theory was 
utilized to explore how certain risk factors have an association to the disease in question 
through time or the in the course of an individual’s life (Parekh & Zizza, 2013). This 
theory was utilized to better understand biological, environmental, and psychosocial 
pathways and how they collectively affect the natural history of an individual’s health 
(Parekh & Zizza, 2013). This approach was utilized to examine the association of vitamin 
D and the role it potentially played in development of AMD, which is a disease that 
develops through time. I considered only biological and environmental factors in this 
study. I provide a more detailed explanation in Chapter 2. In Table 1, I present an 
overview of the constructs utilized for this research. 
Table 1 
Overview of Constructs 
Variable  Biological pathway Environmental pathway 
Vitamin D level  X 
Diabetes X  
Age X  
Race X  





Nature of the Study  
Although with conflicting results, several studies have been conducted to better 
understand the association between level of vitamin D and AMD disease development 
and stage of disease. Therefore, the rationale for this study was to evaluate large numbers 
of subjects with the hope to strengthen the results of the data while adding to the existing 
literature. The selection of utilizing the existing NHANES database and running a 
secondary analysis provided the opportunity to have these large numbers. 
The key study variables included vitamin D level; AMD status; and presence of 
diabetes, age, race, and smoking status. In this study, I sought to better understand the 
association between vitamin D level with the development of AMD, while considering 
the covariates of age, race, diabetes, and smoking status.  
In my cross-sectional study, I utilized a quantitative methods approach to 
implement a logistic regression analysis using an existing dataset. The 2005–2008 
NHANES dataset contains serum concentration levels of vitamin D as well as retinal 
fundus photographs graded and categorized by AMD severity scale. This 2005–2008 
dataset from NHANES was utilized to analyze the association of vitamin D levels to 
AMD severity from an available sample size of 5,604 individuals (Centers for Disease 





Age-related macular degeneration (AMD): A progressive degenerative disease of 
the macula – an area of the retina responsible for visual acuity and color vision (Van 
Lookeren Campagne et al., 2014). 
Early age-related macular degeneration : Generally referred to as dry AMD – is 
characterized by medium drusen >63 µm and ≤125 µm with no AMD pigmentary 
abnormalities, and generally causes only minimal visual acuity impairment (Van 
Lookeren Campagne et al., 2014). 
Diabetes: A disease in which an individual’s blood glucose, or blood sugar levels 
are too high – typically a fasting plasma glucose higher than 7.0 mmol/l (NIH, 2016). 
Fundus imaging eye exams: The process where 2-D or 3-D retinal semitransparent 
tissues are projected using reflected light onto an imaging plane (Abramoff, Garvin, & 
Sonka, 2010). 
Intermediate age-related macular degeneration : Also generally referred to as dry 
AMD – is characterized by large druze >125 µm and/or any AMD pigmentary 
abnormalities, and generally causes only minimal visual acuity impairment (Van 
Lookeren Campagne et al., 2014). 
Late age-related macular degeneration : Also referred to as advanced AMD, this 
condition has two forms: (a) NVAMD (wet/exudative AMD) and (b) GA (Van Lookeren 
Campagne et al., 2014). 
Vitamin D: A fat-soluble vitamin naturally occurring in few foods, added to others 





I utilized data collected from NHANES. The NHANES database is publicly 
available and I assumed that the fundus photos taken have been read and graded 
correctly. I also assumed that the correct sampling and testing methods were utilized for 
quantitative analysis of vitamin D level. In addition, I assumed that individuals that 
participated did so willingly, thereby lessening the chance of bias. These assumptions 
were necessary to the validity of the study being conducted. 
Scope and Delimitations  
The 2005–2008 NHANES database used an oversampling of persons aged 60 
years and older (CDC, 2015). This particular aspect of the data was beneficial for the 
current study as I sought to better understand the association between variables in a 
disease that occurs in the aging population. The nature of the NHANES database 
sampling accounted for why it made sense to use this population to run an analysis 
looking at better understanding a disease in an aging population. In addition, having the 
independent and dependent variables both measured in a manner that minimized recall 
bias contributed to the strength of the data outcomes and conclusions. 
A drawback was that all of the individuals in this population dataset were from 
the United States. It was a large sampling in the NHANES database and was 
generalizable to the overall U.S. population. However, utilizing data from only one 
country creates a challenge in saying the conclusions are generalizable to populations in 





A limitation of the study was the potential for individual participant bias for the 
portions of data that were self-reported. Covariates smoking and diabetes were both self-
reported by participants. Smokers may contribute bias by providing self-reported answers 
they believed were more socially desirable. In addition, medical records indicating 
diabetes diagnosis could have been more accurate than participant self-reports. As stated 
previously, AMD is a disease of those older than 55 years. Memory recall may be 
potentially worse in this age population contributing to recall bias. Other covariates 
included age and race; these are both straightforward and should not contribute to bias 
that influences outcomes. Fortunately, the manner of data collection for both the 
independent variable (vitamin D level) and dependent variable (stage of AMD) 
minimized recall bias. Examiners in a lab tested vitamin D level and masked readers did 
the reading of retinal images (NHANES, 2015). However, the lab method for vitamin D 
measurement changed (discussed further in Chapter 3) from the 2005–2006 and 2007–
2008 data collection years and presents a potential limitation through measurement bias. 
Additional measures were not needed to address limitations of the study.  
Significance 
In the United States, an estimated 1.75 million adults older than 40 years have 
some form of advanced AMD (Cheung & Eaton, 2013). By 2020, that number is 
expected to climb to approximately 3 million (Wong et al., 2014; Brantley et al., 2012). 
AMD is still the leading cause of blindness in the Western world (Brantley et al., 2012). 




blindness prevalence of 8.7% (WHO, 2014). Several risk factors have been associated 
with AMD including age, race, smoking, a number of genetic risk factors, and diet 
(Chew, Clemons, Milton, & Sperduto, 2007; Klein, Peto, Bird, & Vannewkirk, 2004). 
The greatest risk for developing AMD is attributed to age, as data suggested that greater 
than 15% of white women older than 80 years have advanced forms of AMD (Klein et 
al., 2004). AMD has a significant and growing effect on public health and poses 
significant economic and social burdens. By demonstrating that there is an association 
between vitamin D level and development of AMD, this research may effect positive 
social change at a global level. If an association is found and can successfully be 
established, AMD disease progression may be addressed with vitamin D 
supplementation. If identifying this association can lead to a supplement that lessens 
disease progression and AMD patients have better outcomes, then an additional social 
implication includes the potential to a reduced burden on the cost of health care. 
Summary 
AMD is a complicated disease with a growing burden on public health. Several 
potential modifiable risk factors warrant further exploration. There is limited research on 
the association of serum vitamin D levels with AMD disease progression. This study may 
add to the literature on this topic and address this gap in knowledge. If an association 
between the two can be more clearly defined, then the study results may have a 
meaningful effect on AMD disease progression and mitigating the effects on the growing 
future public health burden. If vision can be spared, then patients may have better 




In Chapter 2, I review the existing literature on the topic of vitamin D association 
to AMD. I also discuss how the existing research serves as a foundation for this study and 
a need to learn more. In Chapter 2, I provide a discussion of the literature with a focus on 
the findings as well as challenges. I conclude Chapter 2 with how outcomes and 





Chapter 2: Literature Review 
Introduction 
AMD is a disease of the back of the eye, which can result in blindness if left 
untreated. AMD is classified by four stages: no AMD, early AMD, intermediate AMD, or 
late AMD, with two types of late stage AMD: neovascular (or wet) AMD and GA (or 
dry) AMD (Van Lookeren Campagne et al., 2014; Ferris et al., 2013). It is projected that 
the current estimate of 30–50 million individuals living with AMD will grow to 288 
million by 2040 (Singer, 2014; Wong, 2014). With this growing prevalence and affect on 
the public health system, it will be beneficial to better understand underlying factors that 
contribute to AMD disease development that could potentially be modified. The risk for 
developing AMD may be increased in the presence of vitamin D deficiency (Itty et al., 
2014; Parekh et al., 2007). A limited number of studies have been done that look at the 
association of vitamin D levels and AMD. Vitamin D deficiency is a modifiable risk 
factor that is still not fully understood as it pertains to AMD and warrants further 
exploration. Several studies have been completed that I explored in detail. These studies 
have been largely inconclusive, with conflicting results among them. Some conclude by 
suggesting there is a possible association, whereas others indicate that an association 
between vitamin D deficiency and AMD development does not exist. 
In Chapter 2, I discuss the literature review strategy. In addition, I describe the 
theoretical foundation with a rationale for why I chose it and I examine a review of the 
current literature related to key variables and concepts. Last, I conclude Chapter 2 with a 




Literature Search Strategy 
The search strategy included review of publications that reported on AMD, 
vitamin D, and vitamin D deficiency by searching the following databases: PubMed, 
Academic Search Premier, Science Direct, Google Scholar, and the Walden library. I 
searched these databases for relevant papers that were published on this topic until May 
2016, which included the following search terms in various combinations: age-related 
macular degeneration, vitamin D, vitamin D deficiency, serum vitamin D, risk, AMD 
status, or cross-sectional study. This strategy assisted in identifying studies that examined 
the association of vitamin D to AMD in different types of studies. It is a relatively new 
topic to assess the link between vitamin D level and development of AMD. Therefore, the 
search was not limited in terms of how far back I searched for studies, but the relevant 
literature included was 10 published papers from 2007 to 2016. The two papers from 
2007 were relevant and included because one was the only other NHANES database 
review on this topic and the other evaluated the role of calcitriol/vitamin D on retinal 
neovascularization in animals precipitating the necessity to understand the effect in 
humans (Albert et al., 2007; Parekh et al., 2007). There remains a gap in the literature on 
this topic of vitamin D association to AMD despite the list of studies discussed here. 
Theoretical Foundation 
I introduced the theoretical base for this study in Chapter 1, the life course 
epidemiology model. The life course theory studies biological, environmental, and 
psychosocial pathways that play a role in an individual’s life span as it relates to 




the biological and environmental pathways only. The life course approach is a 
methodology that provides a framework to analyze how risk factors can affect disease 
development in an individual’s life through time. The life course theory was introduced 
in the 1960s by connecting several general principles including social change, social 
structure, and individual action to guiding the foundation of life course research (Giele & 
Elder, 1998). 
This life course theory helps explain disease patterns across populations through 
time and attempts to better understand if and how exposures effect chronic disease 
development. The life course theory may employ either qualitative or quantitative 
approaches. Quantitative approaches include the following: life event history analysis, 
longitudinal studies, as well as cohort and cross-sectional designs. The current research 
utilized a cross-sectional design for data analysis. 
Ben-Shlomo and Kuh (2002) discussed propositions, hypotheses, and challenges 
of the life course approach to chronic disease epidemiology back when increasing interest 
in using this framework began. The life course theory employs an approach that 
examined long-term affect of physical and social exposures throughout gestation, 
childhood, adolescence, young adulthood, and later life attempting to explore how the 
exposures had an effect on chronic disease risk (Ben-Shlomo & Kuh, 2002). There have 
been chronic disease cohort studies conducted in the past that implemented the life course 
theory by collecting baseline measures, then following patients and analyzed changes in 
exposure data based on the follow up metrics collected. A challenge of this type of 




weight and socioeconomic status) being accounted for, there existed a temporal 
relationship between variables that was not considered (Ben-Shlomo & Kuh, 2002).  
Considering there are multiple factors or exposures that play a role in disease and 
the significance of understanding the timing of the exposures, it should come as no 
surprise that disease risk is affected by the exposures in multiple ways (Ben-Shlomo & 
Kuh, 2002). The ways the exposures are interrelated should be acknowledged and 
considered. For the purposes of this study, a cross-sectional approach was utilized to look 
at a snapshot of multiple factors and how they each played a role in development of 
disease. Further research can be conducted to look more closely at the temporal 
relationship between the variables. 
Ben-Shlomo and Kuh (2002) postulated that it is important to understand the 
natural history of a biological system, the temporal relationship between exposures and 
how across different periods through the life course that the exposures can influence 
biological development differently. For example, an exposure earlier in life may not 
necessarily have an appreciable effect on an individual’s disease development rate or 
health decline in the same way that it might if the same exposure happened later (Ben-
Shlomo & Kuh, 2002). Ku and Ben-Shlomo (2004) share an example of how an early life 
exposure can reduce lung function potential, but by comparison the mid to later life 
exposure accelerates the age-related decline even further. This observation makes a case 
for the following assumption: there is a critical period that an exposure can have a lasting 
or lifelong effect on a biological system or affect the development of disease (Kuh & 




exposure would send a person on a longer path of decline that started sooner resulting in 
a worse outcome through time. If vitamin D level does affect development of AMD 
disease or disease progression, it should be considered at what point is it important to 
manage vitamin D levels through supplementation that has the greatest chance to reduce 
the risk of disease. This could be explored later, but a critical period may exist that 
vitamin D level as an exposure for disease poses the greatest risk. If so, it is possible that 
the critical period relates to the temporal relationship it plays with the other variables.  
The life course epidemiology model makes sense for this research because it 
provides a framework for understanding how behavioral changes can affect disease 
prevention and may interrupt a disease cycle (Parekh & Zizza, 2013). The current 
research attempts to understand if modifying vitamin D levels in deficient individuals can 
interrupt the AMD disease cycle by slowing or preventing disease progression and 
address this gap in the literature. 
Literature Review Related to Key Variables 
AMD Risk Factors 
The Age-Related Eye Disease Study (AREDS) Research Group ran a large 
clinical trial sponsored by the NEI from 1992 through 1998 that enrolled 4,757 
participants with varying degrees of AMD severity in an attempt to learn more about and 
better understand the clinical course, risk factors, and prognosis of AMD and age-related 
cataracts (AREDS, 2005). The primary results at the end of the study in 2001 concluded 
that the AREDS vitamin supplement that was studied was successful in slowing or 




resulted in many subsequent papers and analysis to further understand AMD and 
confirmed or established various associated risk factors. Among them were the risk 
factors of age, race, smoking status, and diabetes that were included in this study as 
covariates.  
Age. AMD is a progressive disease that can ultimately lead to GA or NVAMD as 
individual’s age. AMD prevalence has been demonstrated to be age related in multiple 
studies. The AREDS study found increasing age (60 years and older, up to 80 years old) 
to be a risk factor for NVAMD and GA (AREDS, 2000). Chew and colleagues (2014) 
confirmed age as a risk factor in the subsequent AREDS2 study. The age risk factor 
continues to increase as the individual becomes older (Friedman et al., 2004; AREDS, 
2000). According to the Chew and colleagues (2014) AREDS report, increasing age 
causes risk progression to the advanced form of AMD to go up. A pooled analysis from 
three large population-based studies, the Beaver Dam Study, the Rotterdam Study, and 
the Blue Mountains Eye Study that included 14,752 participants demonstrated age to be a 
risk factor with a clear association across AMD subtypes and all studies (Smith et al., 
2001).  
Race. When analyzing race as a risk factor, multiple large population based-
studies have indicated being Caucasian presents the greatest risk (Friedman et al., 2004). 
Combining the Beaver Dam Eye Study, the Blue Mountains Eye Study, the Rotterdam 
Study, and the AREDS study including 1000’s of participants, all have found being white 
versus other races presented the greatest risk in developing AMD (Chew et al., 2014; 




reported that more than 1 in 10 Caucasians aged 80 years and older has the advanced 
form or neovascular form of AMD (Friedman et al, 2004). Hispanic persons were found 
to have the lowest rate of AMD when compared to white and black counterparts 
(Friedman et al., 2004). The current study attempted to explore the association of race to 
AMD even further. 
Smoking. Smoking has been extensively studied and fairly well established as a 
risk factor to AMD. The AREDS study found smoking to be a risk factor associated to 
the advanced neovascular form of AMD (nAMD) (AREDS, 2000). Chew and colleagues 
(2014) also found an association between smoking and AMD disease and found smoking 
to be the greatest risk in the oldest group of individuals (age 75 to 80 years old) that were 
in the most severe AMD category at baseline. The Blue Mountains Eye Study that 
included 3,654 participants, found smoking at the time of baseline exam was associated 
with an increased risk of both incident GA as well as the late form of AMD (Wang et al., 
2007; Tomany et al., 2004). Furthermore, it has been found in multiple studies that 
current smokers were at higher risk than both past and non-smokers of developing 
incident AMD (Chew et al., 2014; Tomany et al., 2004). Tomany and colleagues (2004) 
reported that current smokers are 6.19 times more likely and past smokers were 5.52 
times more likely to develop NVAMD than their non-smoking counterparts. 
A ten-year follow-up of the Blue Mountains Eye Study that included 2,454 
participants continued to demonstrate smoking association to AMD (Wang et al., 2007). 
Smith and colleagues (2001) reported that smoking was the principal known preventable 




including 14,752 individuals. This pooled analysis of the Beaver Dam Study, Rotterdam 
Study, and Blue Mountains study found tobacco smoking to be the only factor, apart from 
age, to demonstrate a clear association to both types of AMD (the neovascular form as 
well as GA) across all studies (Smith et al., 2001). At the time this research was 
conducted, smoking status presented the most easily modifiable risk factor that can affect 
AMD disease incidence and progression. 
Diabetes. Diabetes is a major public health issue in the United States and 
continues to increase in prevalence. As prevalence increases, so does the demand on 
health care facilities through increased amount of disability, loss of productivity, and in 
some cases premature mortality (Rahman, Rahman, Ismail, & Rashid, 2007). 
Microvascular and macrovascular comorbidities are common in patients with diabetes 
(Rahman et al., 2007). Diabetes has been studied as a potential risk factor to association 
for development of AMD, a microvascular disease. The AREDS study (2005) found a 
weak association of diabetes as a risk factor to AMD based on medical history that 
reported the individual was under treatment for diabetes. In addition, the Blue Mountains 
Eye Study found having diabetes to be associated with the development of incident GA 
(Tomany et al., 2004). Diabetes as a risk factor for AMD still has limited data to support 
it. Exploring this risk factor further in the current study had the greatest potential of the 
covariates to add to the existing gap in the literature on exploring AMD risk factors. A 
better understanding of the association of diabetes to AMD broadens the scope of further 




Vitamin D. Using the aforementioned literature research strategy, ten research 
papers that include similar constructs of interest and the cross-sectional methodology are 
discussed in further detail. Of the ten papers, six studies (spanning from 2007 through 
2015) utilized cross-sectional methodology similar to the scope of this study. The other 
four studies included: a study conducted by Albert and colleagues (2007) done in 
animals, a case series study done by Seddon et al. (2011), a prospective combined 
systems analysis by Morrison and colleagues (2011) including a family-based cohort as 
well as multiple case control cohorts, and a retrospective longitudinal analysis study done 
by Day and colleagues (2012). 
Of all the research that has been done on this topic so far, most of the various 
researchers have utilized the cross-sectional study design approach, with the exception of 
the longitudinal cohort study done by Day et al. (2012), case series by Seddon et al. 
(2011), and prospective case control study by Morrison et al. (2011). The cross-sectional 
approach allows the researcher to view the association between a variable and a disease at 
a single point in time. The researchers that utilized this approach to attempt to better 
understand the association between vitamin D level and AMD disease are discussed in 
further detail.  
Strengths of the cross-sectional study approach on this specific area of study 
include: these studies are relatively quick and easy to conduct; the data on selected 
variables is only collected once; multiple exposures and outcomes can be measured; the 
ability to measure prevalence for all variables being studied; and the importance of 




many listed strengths of the cross-sectional approach contributed to the justification and 
rationale for use of the cross-sectional study design in the current study. The cross-
sectional study design in this particular study allowed for data on the selected 
independent variable of vitamin D level and covariates of age, race, diabetes, and 
smoking status to all be studied from the measurements that were collected for the 
NHANES database.  
A strength of the retrospective longitudinal cohort study conducted by Day and 
colleagues (2012) was that the study design looked at incident cases of AMD, which by 
nature of design required vitamin D deficiency to have occurred before AMD. This can 
be viewed as a weakness in cross-sectional study designs that assess prevalence and does 
not allow assessment of whether deficient vitamin D level or AMD disease occurred first 
(Day et al., 2012). 
Weaknesses of the cross-sectional approach in this specific area of study included 
the following: difficulty in determining, which came first – the outcome or the exposure 
variable; it may be difficult to interpret the associations identified; or inability to measure 
incidence. Weaknesses in the retrospective cohort study conducted by Day and 
colleagues (2012) included: Medicare claims files were utilized for data and this data 
does not contain laboratory findings. 
Weaknesses of the prospective case control cohorts conducted by Morrison and 
colleagues (2011) discussed here included recall bias and sample size. Telephone 
interviews were conducted in this particular study collecting various information. One 




sun exposure reported (Morrison et al., 2011). This data affected how vitamin D as a 
variable played a role in disease. In addition, the sample size of the advance AMD cases 
was very small and only included 10 individuals (Morrison et al., 2011).  
Of the pieces of literature mentioned above, there were conflicting findings as it 
pertained to association of vitamin D to AMD. Based on these conflicting findings and 
limited number of studies conducted thus far, it would be plausible to consider the 
existing cross-sectional study attempting to further validate the existing findings. This 
study adds to the literature on the topic of association of vitamin D to AMD. The key 
variables for this study included vitamin D level, AMD status, and the presence of 
diabetes, age, race, and smoking status. With this study, I sought to better understand the 
association between vitamin D level with the development of AMD, while considering 
the covariates of age, race, diabetes, and smoking status. 
Albert and colleagues (2007) set the stage for attempting to better understand the 
role vitamin D played in a variety of eye diseases that contained a neovascular 
component by examining calcitriol (1,25-hydroxyvitamin D3) in an animal model. A 
mouse oxygen-induced ischemic retinopathy (OIR) model was utilized to evaluate the 
role of calcitriol (Albert et al., 2007). Results from this mouse model in the study by 
Albert et al. (2007) demonstrated that calcitriol-treated animals showed a significant 
decrease in retinal neovascularization compared to control. These results suggested a link 
of vitamin D level to neovascular driven retinal disease that warranted exploration to 
begin in human studies. This particular study contributed to a gap of the association 





Parekh and colleagues (2007) conducted the first study to attempt to better 
understand the association between vitamin D and AMD. This first study utilized a cross-
sectional approach to evaluate the third NHANES from 1988 through 1994 (Parekh et al., 
2007). The study was attempting to find additional risk factors and considered vitamin D 
because sunlight exposure had been suggested as a potential risk factor (Klein et al., 
2004; Taylor et al., 1992). Parekh and colleagues (2007) explored the association of food 
and supplement sources of vitamin D to prevalence of AMD. The final analysis from the 
NHANES III utilized a logistic regression to study data from 7752 individuals and found 
vitamin D to be inversely associated to early AMD, but did not find the same association 
to advanced AMD (Parekh et al., 2007). Parekh and colleagues (2007) study was limited 
by having a small number of only 10 individuals in the advanced AMD group. However, 
the paper set the stage for justifying further research to confirm these findings. As a 
result, six subsequent cross-sectional studies were conducted as follow up in attempt to 
better understand the suggested association. 
Millen et al. (2011) and Golan et al. (2011) published the subsequent cross-
sectional studies on this topic and published conflicting results within the same year. 
Millen and colleagues (2011) were the second study that demonstrated a relationship by 
confirming an association of vitamin D status to development of AMD in Caucasian 
postmenopausal women from the Carotenoids in Age-related Eye Disease Study 
(CAREDS) population. AMD classification in this study was based on retinal fundus 




2004 (Millen et al., 2011). This cross-sectional study model utilized a logistic regression 
statistical analysis method to evaluate the association of serum vitamin D concentrations 
from multiple sources (dietary, supplement, and sunlight) to prevalence of AMD in a 
study population of 1,313 women (Millen et al., 2011).  
Millen and colleagues (2011) did not find a protective effect from reported direct 
sunlight hours. However, analyses of this postmenopausal sample of women confirmed 
the protective effects of vitamin D status to prevalence of AMD, similar to the results 
from Parekh and colleagues (2007). A limitation of this study was that the conclusions 
could only be extrapolated to Caucasian postmenopausal women. In addition, there was a 
potential for recall bias in this study as sunlight exposure since the age of 18 years of age 
was self-reported by participants (Millen et al., 2011).  
Golan and colleagues (2011) utilized a cross sectional study approach to evaluate 
the connection between vitamin D levels and AMD in a study population including 
members of the Maccabi Healthcare Services (MHS) aged 60 years or above. The study 
population included 9,176 individuals – 1,045 with AMD and 8,124 non-AMD subjects 
(Golan et al., 2011). Golan et al. (2011) expected to find that AMD patients would have 
lower levels of vitamin D compared to their non-AMD counterparts, but instead they 
found higher levels of vitamin D were not associated with lower prevalence of AMD. 
Potential limitations of this study included: food and supplement intake of individuals 
was not accounted for; nor was the amount of sun exposure (Golan et al., 2011). A 




study, which made it unlikely that the negative results were a result of a type II error 
(Golan et al., 2011). 
Two large cross-sectional epidemiology studies investigating the association of 
vitamin D with AMD were conducted in 2014; one by Kim et al. (2014) and another by 
Itty and colleagues (2014). The three large epidemiologic studies prior generated 
conflicting results (Parekh et al., 2007; Millen et al., 2011; Golan et al., 2011). The study 
by Itty et al. (2014) concluded with similar findings to Parekh and colleagues (2007) and 
Millen et al. (2011). Whereas Kim et al. (2014) concluded with conflicting results 
suggesting there was an inverse association between high levels vitamin D and late AMD 
in men, but not in women.  
Kim et al. (2014) evaluated a large sample of 17,045 individuals from the Korean 
National Health and Nutrition Examination Survey (KHANES) from 2008 to 2012. This 
study defined AMD in two categories, early and late. Early AMD was defined by 
presence and type of drusen, whereas late AMD was defined by the presence of wet 
(nAMD) or dry AMD (GA) (Kim et al., 2014). Simple and multiple logistic regression 
statistical methods were utilized in this study and results found the prevalence of late 
AMD was inversely associated with high vitamin levels in men but not in women (Kim et 
al., 2014). There was not a correlation found for early AMD in either men or women 
(Kim et al., 2014).  
A strength of the study by Kim et al. (2014) was the large sample size. However, 
there were several limitations that included: inability to adjust for seasonal variation in 




data on individuals that had their wet AMD treated with antivascular growth factors, and 
last the lack of detailed data on sunlight exposure (Kim et al., 2014). Sunlight exposure 
may be variable throughout the year and was not accounted for in this study, but it is 
questionable if the Asian population demonstrated seasonal variation in vitamin D status 
(Kim et al., 2014). 
Itty and colleagues (2014) sought to explore the association of vitamin D 
deficiency to NVAMD and nonneovascular AMD (NNVAMD) compared to matched 
controls from a Duke University Medical Center population (aged 55 years and older) 
from July 1997 through November 2011. A total of 462 participants whose vitamin D 
levels had been measured were included in the study: 146 with NVAMD, 216 with 
NNVAMD, and 100 matched controls (Itty et al., 2014). This study done by Itty et al. 
(2014) found higher rates of vitamin D deficiency in the NVAMD group compared to 
those in the NNVAMD group and matched controls. There were limitations to this study, 
including the lack of temporal connection that goes along with a retrospective review. 
These findings were consistent with some of the previous studies mentioned and justify 
further review. 
Cougnard-Gregoire and colleagues (2015) conducted the most recent cross-
sectional population based study to explore the association between vitamin D deficiency 
and AMD. The study included 697 individuals from an elderly population (aged 72.7 + 
4.4 years) in Bordeaux France (Cougnard-Gregoire et al., 2015). Methods included 
collection of plasma vitamin D concentrations collected from 1999–2001 compared to 




al., 2015). Early AMD was defined by drusen whereas late AMD was defined by 
NVAMD or GA (Cougnard-Gregoire et al., 2015). The study found prevalence of 
vitamin D deficiency to be very high at 83.2%, yet no associations of vitamin D status 
were found with any stage of AMD (Cougnard-Gregoire et al., 2015).  
A limitation of the study by Cougnard-Gregoire and colleagues (2015) was the 
small number. However, there were several strengths including: objective measurement 
of vitamin D, blood samples taken at different times of the year, and confounders such as 
BMI, sociodemographic status, use of certain medications, factors related to vascular 
diseases, relevant genetic polymorphisms (Cougnard-Gregoire et al., 2015). The results 
reported in the Cougnard-Gregoire et al. (2015) study that did not support a role of 
vitamin D to AMD were similar to what Day et al. (2012) found as well as Golan et al. 
(2011). The existing evidence of an association between vitamin D level and AMD status 
were inconsistent and warranted further study. 
Longitudinal Cohort Study 
Day and colleagues (2012) conducted a retrospective longitudinal cohort study in 
Medicare beneficiaries examining a possible association between vitamin D deficiency 
and subsequent AMD diagnosis (of either the neovascular or non-neovascular form). 
Medicare 5% claims files from 2004 through 2006 were utilized to identify a patient 
population of 6,966 individuals with vitamin D deficiency (Day et al., 2012). Individuals 
with an AMD diagnosis that preceded the vitamin D deficiency diagnosis were excluded 
(Day et al., 2012). Results from this study did not find an association of vitamin D 




statistically significant (Day et al., 2012). Although the findings of Day et al. (2012) of 
no association of vitamin D levels to AMD were similar to those of Golan and colleagues 
(2011), they were contrary to what several previous studies had shown. 
A strength of the study by Day and colleagues (2012) was the design looked at 
incident cases and therefore differed from the other studies mentioned because in this 
study it was known that vitamin D deficiency occurred first (Day et al., 2012). This was 
the first study to examine incident cases rather than prevalence of AMD disease (Day et 
al., 2012). A weakness of this study was lack of laboratory results from the type of claims 
data utilized (Day et al, 2012).  
Case Series Study 
Seddon and colleagues (2011) conducted a case series study to evaluate the affect 
of behavioral and nutritional factors (including vitamin D dietary intake) on AMD in 
Caucasian male monozygotic twins. Fundus photographs that were graded by Wisconsin 
Grading System were utilized to evaluate stage of disease (Seddon et al., 2011). The 
Wilcoxon signed-rank test and linear regression statistical models were utilized to assess 
the associations between the various nutritional and behavioral characteristics (including 
vitamin D level) and stage of AMD disease (Seddon et al., 2011). The results of this 
study found dietary intake of vitamin D to be inversely associated with AMD, drusen 
size, and drusen area (Seddon et al., 2011). Although they explored different population 
types, the results of this case series by Seddon et al. (2011) along with those of the cross-




supplemented the original findings by Parekh and colleagues (2007) that suggested there 
was an association between vitamin D level and AMD disease status.  
Prospective Cohort Studies 
Morrison and colleagues (2011) utilized a family based cohort study of 50 sibling 
pairs to examine vitamin D levels compared to AMD. Data on vitamin supplementation 
was collected via questionnaire and UV exposure was based on location of where 
individuals lived for the majority of their lives (Morrison et al., 2011). Limitations of this 
type of data collection included recall bias as it pertains to vitamin D supplementation 
and quantification of sunlight exposure is difficult to assess at best. Results from this 
study suggested a trend toward lower levels of vitamin D in the siblings with NVAMD 
compared to higher concentrations of vitamin D in the unaffected counterparts (Morrison 
et al., 2014). However, the difference was not statistically significant. This study done by 
Morrison et al. (2014) was the first to detect a genetic association between vitamin status 
and AMD and is discussed further in Chapter 5. 
The limited number of studies discussed above on the topic of vitamin D 
association to AMD generated inconsistent findings and suggested further exploration 
was needed. There remains a gap in the literature on this topic and more research on the 
association of vitamin D status to AMD needs to be done. 
Summary and Conclusions 
The themes in the literature on this topic to date suggest data is inconclusive. 
Most of the studies that have been done exploring the topic of the association of vitamin 




levels have been shown to be protective in a variety of different conditions (Morrison et 
al., 2011). What is not known is how exactly vitamin D plays a role in prevalence of 
AMD disease. The limited number of studies on this topic in recent years has found 
conflicting results and suggests that more research needs to be done. The present study 
explored in a large sample size the association of vitamin D to AMD status and adds to 
the existing literature. Using the NHANES database, the association between vitamin D 
level and AMD progression was investigated here.  
In Chapter 3, I discuss the research design and rationale for this study. I review 
the methodology, including: the population, sampling, recruitment, participation, data 
collection, and instrumentation. I conclude Chapter 3 with threats to validity and explore 




Chapter 3: Research Method 
Introduction 
AMD is a progressive disease that can ultimately lead to one of two forms of the 
disease: GA or NVAMD. The most common type of AMD is the nonneovascular form 
(dry) or GA. The neovascular, or wet, form of AMD is the leading cause of blindness in 
older adults affecting an estimated 1.6 million adults older than age 50 years in the 
United States (Melnikova, 2005). Approximately 200,000 new cases of the neovascular 
form of AMD are diagnosed in the United States each year (Melnikova, 2005). Limited 
data supports the suggestion of a possible association between vitamin D status and 
AMD. The purpose of this study was to evaluate the association between vitamin D and 
AMD further.  
Currently, it is not clear whether there is an association between vitamin D 
deficiency and AMD. There is limited data on this topic with conflicting results. The 
findings from this study may support the importance of monitoring and maintaining 
healthy vitamin D levels. This particular cross-sectional study design using NHANES 
data from 2005–2008 used a large population based data sample and tested the five 
hypotheses listed in Chapter 1. The first of these hypotheses attempted to understand the 
association between vitamin D level (high versus low) and the development of AMD. 
The subsequent four hypotheses explored the association of diabetes, age, race, and 




In Chapter 3, I discuss the research method. In addition, I describe the 
instrumentation along with threats to validity and ethical procedures. I conclude Chapter 
3 with a summary of the study design and methodology. 
Research Design and Rationale 
In this cross-sectional analysis, I utilized the NHANES data from 2005–2008 to 
test the association between independent variable vitamin D and dependent variable 
AMD as well as covariates age, race, smoking status, and diabetes. This research design 
was similar to some of the other research studies on this topic. The cross-sectional 
research design provides several advantages for this type of study including: cross-
sectional studies are relatively quick and easy to conduct; the data on selected variables is 
only collected once; multiple exposures and outcomes can be measured; the ability to 
measure prevalence for all variables being studied; and the importance of understanding 
the prevalence for the disease being studied in a specific population (Giele & Elder, 
1998). The many listed strengths of the cross-sectional approach contribute to the 
justification and rationale for use of the cross-sectional study design in the current study. 
In this particular study, the cross-sectional study design allowed for data on the selected 
independent variable of vitamin D level and covariates of age, race, diabetes, and 
smoking status to all be studied from the measurements that were collected in the 2005–
2006 and 2007–2008 NHANES database. 
In my study, I examined a specific point in time to assess the relationship between 
the independent variable vitamin D and the outcome variable AMD, as well as the 




snapshot in time represented the current status of the disease AMD and the tested factors 
in a large nationally representative sample of the population. The results from this 
analysis are generalizable to the greater population as to whether associations were 
present between the tested variables. Data from this study were extracted from the 
NHANES database according to the variables listed in Tables 3 through 6. The total 
sample sizes for NHANES 2005–2006 and 2007-2008 were 9,950 and 9,762, respectively 
(CDC, 2015b). AMD is a disease that is most likely to occur after the age of 60 years, but 
the disease can occur at a younger age. Therefore, I restricted the age cutoff for the 5,604 
sample size to adults aged 40 years and older because AMD is a disease of the aging 
population and prevalence increases with age. In this cross-sectional study, I utilized the 
NHANES database seeking to understand the association between vitamin D and AMD 
including covariates age, race, diabetes, and smoking status addresses an important gap in 
the literature. 
NHANES Dataset 
NHANES is a program that began in the early 1960s designed to assess and study 
the health of children and adults in the United States (CDC, 2015a). NHANES is a 
program of the National Center for Health Statistics (NCHS), which is a part of the 
Centers for Disease Control and Prevention (CDC).  
The NHANES population is a nationally representative sample across the United 
States taken of about 5,000 individuals each year (CDC, 2015a). NHANES over-samples 
individuals aged 60 years and older, African Americans, and Hispanics in order to 




interview of this population included socioeconomic, demographic, dietary, and health-
related questions (CDC, 2015a). The examination portion was carried out by highly 
trained medical professionals and included medical, dental, physiological measurements, 
and laboratory tests (CDC, 2015a).  
Data Collection  
NHANES survey data was collected from conducting interviews, physical 
examinations, and drawing samples for laboratory testing (CDC, 2013). Interviews took 
place in respondents’ homes and health measurements were performed in mobile centers 
that were equipped to travel throughout the country (CDC, 2015a). The interviews 
collected person-level demographic, health, and nutrition information, in addition to 
information about the household (CDC, 2013). The examination included collecting 
physical measurements, a dental examination, and the collection of blood and urine 
samples for laboratory testing (CDC, 2013). 
The study team (many of whom were bilingual in English and Spanish) that 
conducted these assessments and collected the information and data included a physician, 
dietary and health interviewers, and medical and health technicians (CDC, 2015a). 
Advanced computer systems made it possible for interviewers to use notebook computers 
and electronic pens to collect information on site. The information was then transmitted 
to the NHANES database through devices that included digital scales and stadiometers 
(CDC, 2015a). To ensure privacy, respondents were able to enter sensitive information 




To encourage participation, the local media was allowed to share information 
about the survey. In addition, transportation was provided to and from the mobile center 
if needed by the participants (CDC, 2015a). The data collected from respondents was 
available to the NCHS staff within 24 hours, expediting the ability to share results with 
the public. NHANES data is provided to the public at no charge. 
Sampling and Sampling Procedures 
The type of sampling methodology changed from NHANES 2005–2006 and 
2007–2008 years. All Hispanics (not just Mexican-Americans) were oversampled in the 
2007–2008 dataset. The sampling frame for NHANES included all ages of the 
noninstitutionalized civilian population of the United States (CDC, 2013). Predesignated 
domains of sex-age groups for black persons, Mexican-American persons, and income-
sex-age groups for other persons were utilized for oversampling in 2005-2006 (CDC, 
2013). Predesignated domains of sex-age groups for non-Hispanic black persons, 
Hispanic persons, and income-sex-age groups for other persons were utilized for 
oversampling in 2007–2008 (CDC, 2013). 
The sample size from 2005–2006 and 2007–2008 included 10,348 and 10,149 
individuals respectively. There were 7,081 individuals in the 2005–2008 combined 
dataset that were 40 years and older (Klein et al., 2011). Of those, there was a final 
sample total of 5,604 individuals from NHANES 2005–2008 of which there were 
gradable fundus photographs that have been included for the AMD analysis purposes of 




white individuals, 401 other Hispanic individuals, 1,139 non-Hispanic black individuals, 
864 Mexican American individuals, and 183 individuals of other races/ethnicities. 
 G*Power 3.1 statistical software was utilized to run a power analysis and 
compute the required sample size for this study. A priori is the ideal type of power 
analysis and is done before a study takes place (Mayr, Erdfleder, Buchner, & Faul, 2011). 
An a priori power analysis was conducted using a two-tailed z test for linear regression 
with an alpha of 0.05 for statistical significance, a power of 90%, and an odds ratio of 
1.2, which powered it to detect a weak association. According to Monson (1990) an odds 
ratio below 1.2 is not powered to indicate an association. The probability utilized for this 
power analysis was 0.065 because the prevalence or probability of having any AMD in 
the United States based on the 2005–2008 NHANES survey data was 6.5% (Klein et al., 
2011). Based on the power analysis conducted using G*Power statistical software, the 
minimum sample needed to detect a difference was 5,156. The entire sample size 
available of 5,604 was utilized. Evaluation of the association of vitamin D to AMD using 
this sample contributed to understanding if there was an association and adds to the 
literature on this topic. 
Study Variables 
Dependent Variable: AMD 
In the 2005–2006 and 2007–2008 datasets, AMD was determined by information 
on the 3-level severity classification (no ARM, early ARM, or late ARM) of AMD from 
the worse eye (CDC, 2015b). Digital images using a Canon CR6-45NM Opthalmic 




participants aged 40 years and older (CDC, 2005). Fundus photo images were read twice 
by an experienced reader using a modification of the Wisconsin Age-Related 
Maculopathy Grading Sytem (CDC, 2005). Early ARM was defined by presence or 
absence of drusen and/or pigmentray abnormalities (CDC, 2015b). Late ARM was 
defined by exudative ARM signs and/or GA (CDC, 2015b). In order to run a binary 
logistic regression statistical analysis, ARM codes for 1 = early ARM and 2 = late ARM 
were combined and any AMD was defined as early and late AMD. For the purposes of 
this study, the eye with the worst severity of lesion was utilized.  
Independent Variable: Vitamin D 
In the 2005–2006 and 2007–2008 datasets, vitamin D level was determined from 
analysis of a serum sample that was collected from participants at a mobile examination 
center (MEC) (CDC, 2015b). The staff members were observed for equipment operation, 
specimen collection and preparation, and testing procedures (CDC, 2015b). In the 2005–
2006 dataset, the diasorin 25OHD assay method was utilized to determine vitamin D 
levels from the individual’s serum (CDC, 2015b). In the 2007–2008 dataset, the vitamin 
D lab method changed and utilized an ultra-high performance liquid chromatography-
tandem mass spectrometric method to calculate a total 25OHD that was the sum of 
measured 25-hydroxyvitmain D2 (25OHD2) and 25-hydroxyvitamin D3 (25OHD3) 
(CDC, 2015b). 
Covariates 
Covariates for this study included age, race, smoking status, and diabetes; 




smoking status based on how they answered if they had ever smoked a cigarette or 
smoked at least 100 cigarettes in life, and if they had ever been told by a physician that 
they have diabetes.  
Variables: Coding and Questions 
This section outlines the NHANES dataset questions and coding that was utilized. 
I collected the data from the NHANES 2005–2006 and 2007–2008 datasets. 
Demographic data. Demographic covariates age and race were part of the 
NHANES datafile ‘Demographic Variables and Sample Weights’ Doc file DEMO_E.xpt 
that were collected at the time of screening interview for both data years 2005–2006 and 
2007–2008. Age was recorded in years at the time of screening interview. In the 2005–
2006 dataset, responses of age 85 years and older were all coded as 85. In the 2007–2008 
dataset, responses of age 80 years and older were all coded as 80. Race/ethnicity were 





Baseline Characteristics: 2005–2006 and 2007–2008 
Variable name Description and coding Variable 
type 
Study code 
RIDAGEYR Age at screening 
Adjudicated - recode  
Categorical 0 to 79, 80 (2007–2008) 
RIDAGEYR Age at screening 
Adjudicated - recode  
Categorical 0 to 84, 85 (2005–2006) 
RIDRETH1 Race/ethnicity recode Categorical Mexican American, 
Other Hispanic, Non-
Hispanic White, Non-
Hispanic Black, Other 
Race – Including Multi-
Racial 
 
Laboratory Data. The independent vitamin D variable data was obtained from 
the NHANES datafile VID_D_Doc (2005–2006) and VID_E_Doc (2007–2008). The 
vitamin D lab method from 2005–2006 measured total 25-hydroxyvitamin D. The 
vitamin D method changed for 2007–2008 and the total 25OHD was the sum of 25-




Table 3   
Vitamin D 
Variable name Description and coding Variable type Study code 
LBDVIDMS Vitamin D (nmol/L) Binary High versus low 
LBXVIDMS 250HD2+250HD3 Binary High versus low 
 
Questionnaire Data. Covariate smoking was self-reported by participants as a part of 
NHANES Doc file SMQ_D_Doc (2005–2006) and SMQ_E_Doc (2007–2008). The data 
collected for the variable utilized in the current study was based on if the participant was 
a current smoker or past smoker at the time of questionnaire. Covariate diabetes was a 
part of Doc file DIQ_D_Doc (2005–2006) and DIQ_E_Doc (2007–2008). The diabetes 
status was self-reported by participants as to whether they had ever been told by a 
physician that they had diabetes. The question was answered before the physical 





Covariate: Smoking and Diabetes 
Variable name Description and 
coding 
Variable type Study code 
SMQ040 Do you now smoke 
cigarettes 
Binary  Yes (Every day, Some 
days) or No (Not at 
all) 
SMQ020 Smoked at least 100 
cigarettes in life 
Binary Yes, No 
DIQ010 Doctor told you have 
diabetes (both males 
and females 1 year – 
150 years). Will limit 
to age 40–100 years 
Binary Yes, No 
 
Examination Data. The AMD severity determination variable provided 
information on the 3-level severity classification of AMD regarding the worse eye. Early 
ARM was defined by presence or absence of drusen and/or pigmentary abnormalities. 
Late ARM was defined by signs of exudative ARM and/or GA. For any ARM, codes for 
1 = early ARM and 2 = late ARM were combined. These are presented in Table 5. 
Table 5 
AMD Severity Determination: 2005-2006 and 2007-2008 
Variable name Description and coding Variable type Study code 
OPDUARM ARM, 3 severity levels, 
worse eye 






The NHANES dataset categorized the AMD variables as early, late, and none. 
Fundus photos taken from participants that have been read by experienced Wisconsin 
grading center photographer were utilized to determine AMD status. Similar methods 
have been utilized in other epidemiological studies (the AREDS study for example) to 
diagnose disease with fundus photography that was more closely similar to clinical exam. 
The existing NHANES database utilized for this study relied on fundus photos to 
determine AMD status. This was an appropriate way and more accurate way to assess 
AMD status than patient recall. This eliminated the possibility of including participants 




The data collection instrument I utilized for this dissertation was the NHANES 
existing secondary dataset. NHANES data comprised three levels of data from a 
representative sample of the U.S. noninstitutionalized civilian population: a household 
screener, an interview, and a physical examination (CDC, 2013). When combining 2-year 
survey cycles it is important to combine the cycles using the appropriate weights (CDC, 
2013b). Therefore, I utilized the 4-year examination weights generated from the MEC 
examination for comparisons. I discussed the data analysis of how the four consecutive 




NHANES data is available for public use and therefore permission to use the data 
was not necessary. The Walden University Institutional Review Board (IRB) approved 
this study before being conducted (IRB approval number 10–28–16–0229912). The 
validity and reliability of the NHANES database was evaluated in a comparative analysis 
across three national health surveys that also included the Behavioral Risk Factor 
Surveillance System (BRFSS) and the National Health Interview Survey (NHIS) (Li et al, 
2012). According to Li and colleagues (2012), the results of their study supported the 
external validity and reliability of all three national health surveys (including NHANES) 
and were consistent with previous findings. 
Data Analysis Plan 
I utilized the IBM SPSS Statistics software package to run the statistical analysis 
for this study (IBM Marketplace, n.d.). I utilized a bivariate logistic regression to explore 
the association of vitamin D to AMD. The association of AMD to age, race/ethnicity, 
smoking status, and diabetes were explored individually and those found to be significant 
were included in further analysis using a multivariate logistic regression. Calculations 
included descriptive statistics on the tested association between vitamin D and AMD 
including the covariates. 
Hypothesis 1: There is an association between vitamin D level (high versus low) 
and the development of AMD. This variable data was created from blood draw samples 
that were taken from participants. I ran a binary logistic regression analysis between 




for 1 = early AMD and 2 = late AMD were combined to make this a binary logistic 
regression analysis. 
Hypothesis 2: There is an association between diabetes and the development of 
AMD. This variable data was created from participant responses to the question if they 
have ever had a “doctor told you have diabetes”. Responses included were yes, no, 
borderline, refused, and don’t know. I ran a binary logistic regression analysis between 
diabetes and AMD to test this hypothesis.  
Hypothesis 3: There is an association between age and the development of AMD. 
The participant in response to the survey question reported age at time of screening. The 
age cutoff for the sample was restricted to adults aged 40 years and older because AMD 
is a disease of the aging population and prevalence increases with age. I ran a binary 
logistic regression analysis between age and AMD to test this hypothesis. 
Hypothesis 4: There is an association between race and the development of AMD. 
I ran a binary logistic regression analysis between race and AMD to test this hypothesis. 
This variable data was created from participant self-reported race responses to the survey 
questions on race and Hispanic origin. Responses included were Mexican American, 
other Hispanic, non-Hispanic White, non-Hispanic Black, and other race – including 
multi-racial. 
Hypothesis 5: There is an association between smoking and the development of 
AMD. The variable data was created from participant’s responses to the survey questions 
‘do you now smoke cigarettes’ and have you ‘smoked at least 100 cigarettes in life’. The 




provided - every day, some days, not at all, don’t know, or refuse to answer. The 
following responses to select from in response to have you ‘smoked at least 100 
cigarettes in life’ were provided – yes, no, or refuse to answer. I ran a binary logistic 
regression analysis between smoking and AMD to test this hypothesis. For this statistical 
analysis, answers to the smoking questions were re-coded for 0 = Non-Smoker, 1 = Past 
Smoker, and 2 = Current Smoker. I utilized these answers for analysis in this binary 
logistic regression to test the association between current smoking, past smoking, and no 
smoking to likelihood of having AMD. 
Hypothesis 6: There is an association between vitamin D level and the 
development of AMD after controlling for covariates. I ran a multivariate logistic 
regression analysis between all covariates and AMD to examine whether the combined 
variables predicted AMD and test this hypothesis.  
Threats to Validity 
There are a number of strengths to this study, including that the study utilized a 
nationally represented large population based sample size including multiple 
race/ethnicities. It is also important to consider limitations to internal and external 
validity of this study using the NHANES dataset. The institutionalized population was 
not included in the sample. Fundus photographs were not able to be collected for all 
participants for one reason or another. This should be taken into consideration when 
making generalizations to the entire U.S. population. I assume that the vitamin D 
instrument utilized to measure serum levels was conducted correctly and has not affected 




validity of results. Self-reported data as it pertains to smoking status as well as diabetes 
diagnosis needs to be considered. All of these factors should be taken into account when 
making assessments based on the results of this study. 
Ethical Considerations 
The NHANES data is free to be utilized by the public. Individuals that 
participated in the NHANES survey received compensation and a report of medical 
findings (CDC, 2015a). All of the survey information collected was de-identified and 
kept strictly confidential (CDC, 2015a). Participant’s privacy was protected by public 
laws (CDC, 2015a). There were no ethical concerns related to participant recruitment, 
materials or methods utilized to draw samples, or collection of data for the 2005–2006 
and 2007–2008 NHANES dataset utilized for this dissertation.  
Summary 
I applied the cross-sectional approach to this quantitative study analyzing the 
association between vitamin D and AMD using the NHANES data from 2005–2006 and 
2007–2008. I included additional research areas of the confounding variables of age, 
race, smoking status, and diabetes for analysis. In Chapter 4, I present results of the 
analysis I utilized to test the six hypotheses for this study. In it, I discuss data collection 




Chapter 4: Results 
Introduction 
The purpose of this study was to examine the association between vitamin D and 
AMD. AMD is a destructive eye disorder. Loss of vision translates into an effect on the 
emotional aspects of life, puts individuals at risk for falls, and prevents them from 
interacting with their families. Many dimensions of this study make it important. The 
research questions and corresponding hypotheses were the following: 
RQ1: What is the association between vitamin D level (high versus low) and the 
development of AMD? 
H01: There is no association between vitamin D level (high versus low) and the 
development of AMD. 
Ha 1: There is an association between vitamin D level and the development of 
AMD. 
RQ2: What is the association between diabetes (yes/no) and development of 
AMD? 
H02: There is no association between diabetes (yes/no) and the development of 
AMD. 
Ha 2: There is an association between diabetes (yes/no) and the development of 
AMD. 
RQ3: What is the association between age and development of AMD? 
H03: There is no association between age and the development of AMD. 




RQ4: What is the association between race and the development of AMD? 
H04: There is no association between race and the development of AMD. 
Ha 4: There is an association between race and the development of AMD. 
RQ5: What is the association between smoking (yes/no) and the development of 
AMD? 
H05: There is no association between smoking (yes/no) and the development of 
AMD. 
Ha 5: There is an association between smoking (yes/no) and the development of 
AMD. 
RQ6: What is the association between vitamin D level and the development of 
AMD, after controlling for covariates? 
H06: There is no association between vitamin D level and the development of 
AMD after controlling for covariates. 
Ha 6: There is an association between vitamin D level and the development of 
AMD after controlling for covariates. 
In Chapter 4, I discuss the data collection and I present the descriptive statistics 
for independent, dependent, and potentially confounding variables. I provide the results 
of my analysis of the six research questions. Chapter 4 concludes with a summary and 
transition to Chapter 5. 
Data Collection 
This study utilized data collected from the 2005–2008 NHANES database. The 




health and nutrition of adults and children in the United States. It is a nationally 
representative sample across the United States taken of about 5,000 individuals each year 
(CDC, 2013). NHANES survey data was collected from conducting interviews, physical 
examinations, and drawing samples for laboratory testing (CDC, 2013).  
I downloaded and coded the NHANES dataset per the aforementioned categories 
for analysis with SPSS software. The data was weighted with the NHANES sample strata 
and cluster weights as well as full sample 2-year interview (WTINT2YR) and MEC exam 
(WTMEC2YR) weights according to the NHANES least common denominator method 
(CDC, 2015c; CDC, 2015d). The sample weights were utilized to aid in obtaining an 
unbiased estimate of the population because the sample participants were chosen with 
unequal probabilities. The strata and cluster statements name the variables that form 
strata and identified clusters in the cluster sample NHANES design. 
Results 
A sample of 10,348 and 10,149 individuals were interviewed in the NHANES 
years 2005–2006 and 2007–2008 samples, respectively. From the total, 2,413 and 3,191 
individuals in 2005–2006 and 2007–2008 respectively had gradable fundus photos (CDC, 
2015c). This allowed me to use a combined total sample of 5,604 individuals with 
gradable fundus photos categorized into ARM status for this analysis. Within this 5,604 
partial study sample, there were reported results from all 5,604 individuals on age, 
diabetes status, and race/ethnicity. There were 5,036 individuals in the study sample with 
reported values of vitamin D and 5,602 individuals with reported smoking status. Table 6 




table 6, I present the frequencies and percentages for the categorical variables of the 
study sample, NHANES sample, and percentages by the weighted population sample. 
Table 6 
Respondent Sociodemographic characteristics: Study Sample, NHANES Sample, and 
Weighted Sample to Represent Population 




 Frequency % Frequency % % 
ARM      
Yes 443 7.9 NA NA 7.9 
No 5163 92.1 NA NA 92.1 
Vitamin D 
     
1-9.99 177 3.2 534 2.6 2.0 
10-19.99 1590 28.4 4748 23.2 25.0 
20-29.99 2049 36.6 6414 31.3 43.0 
30+ 1220 21.8 3550 17.3 30.0 
Diabetes      
Yes 831 15.2 1298 6.3 10.6 
No 4773 85.2 18,190 88.7 89.4 
Age      
40-59 2829 50.5 3357 16.4 64.4 
60+ 2775 49.5 3724 18.2 35.6 
Race/Ethnicity      
Non-Hispanic White 3017  53.8 8043 39.2 77.1 
Other Hispanic 401 7.2 1550 7.6 3.2 
Mexican American 864 15.4 5004 24.4 5.4 
Non-Hispanic Black 1139 20.3  4921 24.0 9.6 
Other race 183 3.3  979 4.8 4.7 
Smoking status      
Current smoker 1154 20.6 2408 11.7 20.3 
Past smoker 1731 30.9 2741 13.4 31.2 
Non-smoker 2717 48.5 5752 28.1 48.5 




Results for Research Question 1 
To answer research question 1, “What is the association between vitamin D level 
(high versus low) and the development of AMD?”, I utilized binary logistic regression 
using complex samples for vitamin D level and AMD that were extracted from the 
NHANES database. The study population was n = 5,036. The NHANES dataset reported 
vitamin D levels on only 5,036 individuals from the 5,604 study sample. Vitamin D level 
data was missing or unreported for 568 individuals. Table 7 contains the results from the 
binary logistic regression.  
Table 7 
Individual Logistic Regression Results for Variables Vitamin D: Association with 
Dichotomous Age-related Macular Degeneration 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Vitamin D (ng/ml) .279    
1-9.99 vs. 20-29.99  .409 .209 .801 
10-19.99 vs. 20-29.99  .858 .631 1.168 
≥30 vs. 20-29.99  1.001 .758 1.323 
 
 
The p value of the results of the analysis of the association between vitamin D 
level and AMD were found to be .279. The results in the highest levels of vitamin D (30+ 
ng/ml) had an odds ratio of 1.001 (95% CI: .758 to 1.323) when compared to 20-29.99 
ng/ml. The odds ratio for individuals with vitamin D level 10-19.99 ng/ml was .858 (95% 




the lowest level of vitamin D (1-9.99 ng/ml) was .409 (95% CI: .209 to .801) when 
compared to 20-29.99 ng/ml. These results suggested that overall; vitamin D level was 
not associated with AMD. I did not find a vitamin D level association to AMD to be 
statistically significant in response to research question 1. However, the only comparison 
where the confidence interval does not cross 1 was in the lowest level (1-9.99 ng/ml) 
suggesting that there may be a protective association in the lowest level of vitamin D 
category when compared to individuals with 20-29.99 ng/ml in this sample. Vitamin D 
was the main focus of this analysis; therefore I included it in the multivariate logistic 
regression model for research question 6. I failed to reject the null hypothesis for research 
question 1 (there is no association between vitamin D level (high versus low) and the 
development of AMD) based on the results found for the binary analysis in this study. 
Results for Research Question 2 
To answer research question 2, “What is the association between diabetes (yes/no) 
and development of AMD?”, I utilized binary logistic regression using complex samples 
for diabetes status and AMD that were extracted from the NHANES database. The study 
population was 5,604. The NHANES dataset reported diabetes status on the entire study 
sample of 5,604 with graded fundus photography. Table 8 contains the results from the 





Individual Binary Logistic Regression Results for Variable Diabetes: Association with 
Dichotomous Age-related Macular Degeneration 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Diabetes     
Yes vs. no .272  1.258 .952 1.662 
 
The p value associated with this result (p = .272) indicated there was not a 
statistically significant association between diabetes status and AMD. The odds ratio 
result was 1.258, with a 95% CI of .952 to 1.662, including 1, which means that there 
was not a statistical significance indicating that people with diabetes in this sample were 
not at higher risk for AMD than those without diabetes. Therefore, I left diabetes out of 
the multivariate logistic regression analysis run for research question 6. Based on the 
results found on the association between diabetes and AMD to answer this question, I 
failed to reject the null hypothesis for research question 2.  
Results for Research Question 3 
To answer research question 3, “What is the association between age and 
development of AMD?”, I utilized binary logistic regression using complex samples for 
reported age and AMD that were extracted from the NHANES database. The study 
population was N = 5,604. The NHANES dataset reported age on the entire study sample 






Individual Binary Logistic Regression Results for Variable Age: Association with 
Dichotomous Age-related Macular Degeneration 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Age     
≥ 60 vs. 40-59 ≤.001  5.455 3.773 7.887 
 
The p value result of <.001 indicated a statistically significant association between 
age and AMD. The odds ratio result of 5.455 (95% CI: 3.773 to 7.887) suggested 
individuals in the higher age category (aged 60 years and older) were 5.455 times more 
likely to have AMD than their younger counterparts aged 40-59 years. Therefore, I 
included age in the multivariate logistic regression analysis. I rejected the null hypothesis 
for research question 3 (there is no association between age and the development of 
AMD) based on the results found for this study. 
Results for Research Question 4 
To answer research question 4, “What is the association between race and the 
development of AMD?”, I utilized binary logistic regression using complex samples for 
reported race and AMD that were extracted from the NHANES database. The study 
population was N = 5,604. The NHANES dataset reported race on the entire study sample 
of 5,604 with graded fundus photography. Table 10 contains the results from the binary 





Individual Binary Logistic Regression Results for Variable Race/Ethnicity: Association 
with Dichotomous Age-related Macular Degeneration 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Race/Ethnicity ≤.001    
Other Hispanic vs. 
Non-Hispanic White 








 .333 .227 .489 
Other race vs. Non-
Hispanic White 
 .608 .321 1.152 
 
The p value result of <.001 indicated a statistically significant association between 
race/ethnicity and AMD. The odds ratios presented in Table 10 utilized non-Hispanic 
white as the referent. All results suggested that non-Hispanic whites were at higher risk 
of AMD than the other groups. The odds ratio result of .576 (95% CI: .341 to .975) for 
individuals of other Hispanic race/ethnicity suggested non-Hispanic whites were 1.73 
times more likely to have AMD. The odds ratio result of .670 (95% CI: .472 to .950) for 
individuals of Mexican American race/ethnicity suggested that their non-Hispanic white 
counterparts were 1.49 times more likely to have AMD. The odds ratio result of .333 
(95% CI: .227 to .489) for individuals of non-Hispanic black race/ethnicity also showed 
that their non-Hispanic white counterparts were 3 times more likely to have AMD. The 




race/ethnicity suggested non-Hispanic whites were 1.64 times more likely to have AMD. 
I converted these odds ratios to suggest the increased risk for non-Hispanic whites when 
compared to each of the other groups. I found race to be statistically significantly 
associated with AMD and therefore I included race in the multivariate logistic regression 
analysis. I rejected the null hypothesis for research question 4 (there is no association 
between race and the development of AMD) based on the results found using this study 
sample.   
Results for Research Question 5 
To answer research question 5, “What is the association between smoking 
(current/past/non) and the development of AMD?”, I utilized binary logistic regression 
using complex samples for smoking status and AMD that were extracted from the 
NHANES database. The study population was n = 5,602. The NHANES dataset reported 
smoking status on 5,602 individuals from the 5,604 participant study sample. Smoking 
status data was missing or unreported for only 2 individuals. Table 11 contains the results 
from the binary logistic regression.  
Table 11 
Individual Binary Logistic Regression Results for Variable Smoking Status: Association 
with Dichotomous Age-related Macular Degeneration 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Smoking status ≤.001    
Past vs. Non-smoker  1.584 1.229 2.048 
Current vs. Non-
smoker 





The p value result of <.001 indicated a statistically significant association between 
smoking status and AMD. The odds ratio result for past smokers was 1.586 (95% CI: 
1.229 to 2.048) when compared to non-smokers. These results indicate that past smokers 
were 1.58 times more likely to have AMD than non-smokers. The odds ratio result for 
current smokers was .809 (95% CI: .569 to 1.151) when compared to non-smokers 
suggesting that current smokers are 1.23 times less likely to have AMD than non-
smokers. However, the confidence interval does cross 1, indicating that there was no 
difference between current smokers and non-smokers when it comes to having AMD. I 
found smoking status to be statistically significant; therefore, I included smoking status in 
the multivariate logistic regression analysis. I rejected the null hypothesis for research 
question 5 (there is no association between smoking status (yes/no) and the development 
of AMD) based on the results found for this study. 
Results for Research Question 6 
To answer research question 6, “What is the association between vitamin D level 
and the development of AMD, after controlling for covariates?”, I utilized a multivariate 
logistic regression using complex samples for vitamin D level and AMD status after 
including covariates age, race, and smoking status. I found all of the included covariates 
to show statistical significance in each of their individual binary logistic regression 
analyses. Based on the bivariate logistic results, I did not include diabetes in the model. I 
included the entire study population in the multivariate analysis for a total of N = 5,604. 





Multivariate Logistic Regression Results for the Association of Vitamin D Level with 
Dichotomous Age-related Macular Degeneration after Controlling for Age, 
Race/Ethnicity, and Smoking Status 
Characteristic p Odds Ratio 95% Confidence Interval 
 Lower      Upper 
Vitamin D (ng/ml) .553    
1-9.99 vs. 20-29.99 .454 .570 .255 1.271 
10-19.99 vs. 20-29.99 .145 .969 .731 1.284 
≥30 vs. 20-29.99 .156 .924 .683 1.249 
Age ≥ 60 vs. 40-59 <.001 5.004 3.382 7.405 
Race/Ethnicity .011    
Other Hispanic vs. Non-
Hispanic White 
.314 .738 .412 1.323 
Mexican American vs. 
Non-Hispanic White 
.198 .863 .591 1.262 
Non-Hispanic Black vs. 
Non-Hispanic White 
.237 .430 .274 .675 
Other race vs. Non-
Hispanic White 
.456 .647 .289 1.446 
Smoking status .293    
Past vs. Non-smoker .144 1.247 .943 1.649 
Current vs. Non-smoker .209 1.07 .725 1.603 
 
The p value result varied for each independent variable comparison to AMD 
suggesting statistical significance in the multivariate model. For vitamin D, I found the p 
value to be .553, not statistically significant. The results in the highest levels of vitamin D 




29.99 ng/ml. The odds ratio in the lowest level of vitamin D (1-9.99 ng/ml) was .570 
(95% CI: .255 to 1.271) when compared to 20-29.99 ng/ml. The odds ratio for individuals 
with 10-19.99 ng/ml of vitamin D was .969 (95% CI: .731 to 1.284) when compared to 
individuals with 20-29.99 ng/ml of vitamin D. The confidence interval crosses 1 in all 
three comparisons, indicating there was no difference between any of the groups.  
I found the p value for age to be <.001 and statistically significant in the 
multivariate model. For age, older individuals had an odds ratio of 5.004 (95% CI: 3.382 
to 7.405), indicating individuals aged 60 years and older were 5 times more likely to have 
AMD than their younger counterparts. I found age to be associated with AMD in both the 
bivariate and multivariate models. This odds ratio result indicated little to no modifying 
effect occurred when I added the other variables.  
The p value result of .011 for association between race/ethnicity indicated 
statistical significance. I found the odds ratio results for race/ethnicity to be .738 (95% 
CI: .412 to 1.323) for ‘other Hispanic’, .863 (95% CI: .591 to 1.262) for ‘Mexican 
American’, .430 (95% CI: .274 to .675) for ‘non-Hispanic black’, and .647 (95% CI: .289 
to 1.446) for ‘other race’. These results indicated that (similar to the bivariate model) 
non-Hispanic whites were more likely to have AMD than individuals in each race 
category when included in the multivariate model.  
For smoking, I found the p value to be .293 and was not statistically significant in 
the multivariate model. For past smokers, the odds ratio result was 1.247 (95% CI: .943 
to 1.649) when compared to non-smokers indicating that past smokers are 1.247 times 




current smokers was 1.078 (95% CI: .725 to 1.603) when compared to non-smokers. I 
failed to reject the null hypothesis for research question 6 (there is no association between 
vitamin D level and the development of AMD after controlling for covariates) based on 
the results found for this study. I compared the six models, the five univariate logistic 
regressions, and the multivariate logistic regression using Pseudo R2 and present them in 
Table 13.  
Table 13 
Cox and Snell Pseudo R2, Nagelkerke Pseudo R2, McFadden Pseudo R2 Values by Model 
Model Cox and Snell Nagelkerke McFadden 
Univariate    
Vitamin D .001 .002 .002 
Diabetes .000 .001 .001 
Age .040 .104 .084 
Race/Ethnicity .005 .013 .010 
Smoking status .004 .011 .009 
Multivariate .043 .110 .089 
 
Cox and Snell R2, Nagelkerke R2, and McFadden R2 values (sometimes referred to 
as Pseudo R2 values) are methods of calculating explained variation and I utilized these to 
compare models. I included these in the analysis to understand which model fits the best 
in relation to the other models. The Cox and Snell, Nagelkerke, and McFadden pseudo R2 
values for vitamin D ranged from .001 to .002, for diabetes ranged from .000 to .001, for 
age ranged from .040 to .104, for race ranged from .005 to .013, and for smoking status 
ranged from .004 to .011. In the multivariate model, the Cox and Snell, Nagelkerke, and 




combined explained 4.3% to 11% of the variance in the model and the majority of the 
variance was explained by age. In addition, this indicated that the multivariate model was 
an improved model compared to the bivariate models. As I expected, the multivariate 
model demonstrated that it was the best model by having the highest pseudo R2 values. 
These results demonstrate that the multivariate model provided the best fit, though it was 
not predictive of AMD.  
Summary 
Based on the results found from the analysis in this study, I failed to reject the 
null hypotheses from the individual research questions 1 (there is no association between 
vitamin D level (high versus low) and the development of AMD) and research question 2 
(there is no association between diabetes (yes/no) and the development of AMD). I 
rejected the null hypotheses for research questions 3, 4, and 5. I concluded that there were 
statistically significant associations between age, race, and smoking status in individual 
comparisons to AMD status. I failed to reject the null hypothesis for research question 6 
(there is no association between vitamin D level and the development of AMD after 
controlling for covariates) because results indicated that there was not a statistically 
significant association (p = .553) between vitamin D level and presence of AMD in 
participants when controlling for covariates age, race, and smoking status. 
In Chapter 5, I discuss and interpret the results described in Chapter 4. I interpret 
these results in the context of existing theories based on the current literature on the topic 
of vitamin D association to AMD. In addition, I review the strengths and limitations of 




recommendations for further research on the topic based on the findings, and last review 




Chapter 5: Discussion  
Introduction 
In this cross-sectional study, I utilized the NHANES existing database to evaluate 
the association between vitamin D and AMD, while also examining the association 
between covariates diabetes, age, smoking status, and race independent of AMD. I found 
covariates age, race, and smoking status to be statistically significant and I included them 
in a multivariate model testing association between vitamin D and AMD. In Chapter 5, I 
provide interpretations of the data findings, review limitations of the study, discuss 
recommendations based on the findings, provide implications for social change, and, last, 
provide conclusions to the study. 
Interpretation of the Findings 
Overall, the results from this study failed to suggest an association between 
vitamin D levels to AMD is present with or without the covariates included in the model. 
There was not an association found between vitamin D level and presence of AMD. I 
found an association between age, smoking, and race to presence of AMD in each of the 
bivariate models. Age and race still had an association in the multivariate model. 
However, the smoking association was no longer present in the multivariate model. 
Running the pseudo R2 tests provided a better understanding of how much variation in the 
dependent variable can be explained by the model. The 4.3% to 11% variance results of 
the pseudo R2 test demonstrated that age was the main variable that explained the 
variance. The other variables contributed a minor percentage (1% or less) to the model. 




would demonstrate higher pseudo R2 numbers than each of the individual models. This 
was confirmed in the results found for this analysis. These results suggested that once the 
additional variables of age, smoking status, and race were all added to the model, it 
created a better model. 
Vitamin D and AMD 
In this study, I did not find vitamin D to be statistically significantly associated to 
presence of AMD, even after controlling for covariates. There were not enough patients 
to do an analysis including late AMD. Therefore, I combined early and late AMD as any 
AMD for the analysis. In this cross-sectional study of 5,604 individuals aged 40 years 
and older, only 7.9% of the population had any form of AMD and only 31.6% of the 
population had low levels of vitamin D. Vitamin D levels were broken down into the 
following four categories for the analysis: 1–9.99 ng/ml, 10–19.99 ng/ml, 20–29.99 
ng/ml, and 30+ ng/ml. The reference category for this analysis was 20–29.99 ng/ml, 
based on the normal range for vitamin D level and this category had the largest number of 
individuals in the study sample (n = 2,049). 
A statistically significant association between vitamin D level and AMD was not 
found in either the bivariate or multivariate models. In the multivariate model, vitamin D 
was found to have a p value result of .553 (not statistically significant). The results in the 
highest levels of vitamin D (30+ ng/ml) had an odds ratio of .924 (95% CI: .683 to 1.249) 
when compared to 20–29.99 ng/ml. The odds ratio in the lowest level of vitamin D (1–
9.99 ng/ml) was .570 (95% CI: .255 to 1.271) when compared to 20–29.99 ng/ml. The 




1.284) when compared to individuals with 20–29.99 ng/ml of vitamin D. The confidence 
interval crosses 1 in all three comparisons, suggesting there is no difference between any 
of the groups. 
In the bivariate analysis, the odds ratio in the lowest level of vitamin D (1-9.99 
ng/ml) was .409 (95% CI: .209 to .801) when compared to 20-29.99 ng/ml. The odds 
ratio for individuals with vitamin D level 10-19.99 ng/ml was .858 (95% CI: .631 to 
1.168) when compared to individuals with 20-29.99 ng/ml. The highest levels of vitamin 
D (30+ ng/ml) had the highest odds ratio of 1.001 (95% CI: .758 to 1.323) when 
compared to 20-29.99 ng/ml. The odds ratio went up as vitamin D level went up. 
However, these results suggested that overall vitamin D level was not predictive of 
AMD. The only comparison where the confidence interval did not cross 1 was in the 
lowest level (1-9.99 ng/ml) compared to 20-29.99 ng/ml. Vitamin D serum 
concentrations may fluctuate throughout the year or by season and this was not taken into 
account in the current study.  
The results from the current study provided similar findings (of no association of 
vitamin D status to AMD) to what the most recent similar cross sectional study by 
Cougnard-Gregoire and colleagues (2015) found. The latter study included 697 
individuals from an elderly population (aged 72.7 + 4.4 years) in Bordeaux France 
(Cougnard-Gregoire et al., 2015), considerably less than the current study sample of 
5,604. Cougnard-Gregoire and colleagues (2015) classified AMD as early or late instead 
of presence or no presence of AMD. The current study did not contain a high prevalence 




observed 83.2%. It is possible that because only 31.6% of the population had low levels 
of vitamin D (<19.99ng/ml) and 3.2% of those had extremely low levels (<9.9 ng/ml), 
that it played a role in whether a signal was observed.  
Results from the current study conflict with the results from the cross-sectional 
study conducted by Itty and colleagues (2014) which found a statistically significant 
association when comparing vitamin D levels in individuals with NVAMD (late AMD) to 
those with NNVAMD (early AMD) and controls. Late AMD was very rare in the current 
NHANES study and therefore the early and late AMD individuals needed to be 
combined. It is possible that had the numbers been larger that an association may have 
been observed and there were not enough participants to show an affect. 
The current study utilized data from NHANES that did not provide information of 
whether blood samples were taken during different times of the year. NHANES data also 
does not provide information of location/latitude of participants or source of vitamin D. A 
breakdown of latitude of individuals that participated in the study would have provided a 
better understanding of potential for gaining vitamin D source from sunlight. The study 
sample size of 5,604 was powered to detect a weak association with a power of 90% and 
an odds ratio of 1.2. Therefore, it was not likely that the negative study findings were due 
to a type II error. 
Diabetes and AMD 
In the current study, I did not find diabetes to be statistically significantly 
associated to presence of AMD as a single predictor. The p value result was .272 with an 




significant association between diabetes status and AMD. In the current study, I found 
that people with self-reported diabetes in this sample were not at higher risk for AMD 
than those without diabetes. Therefore, I left diabetes out of the multivariate model. 
Diabetes disease in the eye involves microvascular complications and has been 
studied as a potential risk factor to association for development of AMD in the AREDS 
study and Blue Mountains Eye Study (Tomany et al., 2004; AREDS 2005). The AREDS 
study (2005) found a weak association of diabetes as a risk factor to AMD based on 
medical history that reported the individual was under treatment for diabetes. The Blue 
Mountains Eye Study found having diabetes to be associated with the development of 
incident GA, a different form of AMD than was studied here (Tomany et al., 2004). 
Diabetes as a risk factor for AMD has limited data behind it and studying this covariate 
offered the greatest potential to add the existing literature on this topic. However, the 
results from the current study did not offer a finding to support a weak association or an 
association at all. There is still an opportunity to examine this association further in other 
ways. Perhaps using medical records with physician diabetes diagnosis information 
would be another approach to evaluate this association further. 
Age and AMD 
In this study, I found age to be statistically significantly associated to the presence 
of AMD in both the bivariate and multivariate models. The p value result for age was 
<.001 in both the bivariate and multivariate models. The odds ratio result was 5.455 (95% 
CI: 3.773 to 7.887) in the bivariate model and 5.004 (95% CI: 3.382 to 7.405) indicating 




60 years of age and older were 5 times more likely to have AMD than individuals aged 
40-59 years of age in both models. The age p value was similar in both models whereas 
the p value for other variables vitamin D and smoking status changed. It is likely that age 
had a modifying effect on these other variables. I discuss in further detail in those 
sections. 
The findings reported from the current study regarding age were similar and 
consistent with results in the existing literature from previous studies testing this 
association. The current study findings results were not surprising, as age has been well 
established as a predictor for AMD in multiple large population based studies such as the 
AREDS study, the Beaver Dam Eye study, the Blue Mountains Eye study, and the 
Rotterdam study. All of these studies included age as a risk factor in 1,000’s of 
individuals and found increasing age to be a strong risk factor to development of AMD 
(Chew et al., 2014; Friedman et al., 2004; AREDS, 2000). As such, the term age is now 
included in the AMD disease name. 
Race and AMD 
In this study, I found race/ethnicity to be statistically significantly associated to 
the presence of AMD in both the bivariate and multivariate models. The p value result for 
race/ethnicity was <.001 in the bivariate model and .011 in the multivariate model. The 
odds ratio and confidence interval results for each race and ethnicity category compared 
to non-Hispanic whites suggested a statistically significant association between each race 




presence of AMD than other Hispanics, Mexican Americans, non-Hispanic blacks, and 
other race categories.  
The findings of the current study confirmed what multiple other large population 
based studies have found suggesting non-Hispanic whites are at the greatest risk for 
developing AMD. The Beaver Dam Eye study, the Blue Mountains Eye study, the 
Rotterdam study, and the AREDS study have studied race as a risk factor in 1,000’s of 
individuals and found whites to be more likely to develop AMD (Chew et al., 2014; 
Friedman et al., 2004; AREDS, 2000). The Eye Diseases and Prevalence Research Group 
have reported Hispanics to have the lowest rate of AMD when compared to white and 
black counterparts (Friedman et al., 2004). In contrast, the current study found non-
Hispanic blacks to have the lowest likelihood of having AMD to all other race categories. 
In the current study ‘Mexican American’ (15.4 % of the study population) and ‘other 
Hispanic’ (7.2% of the study population) were labeled separately. It is important to 
consider how it might have affected the results as they compare to ‘non-Hispanic blacks’ 
(20.3% of the study population) if they had been combined together. In the multivariate 
model, the results were similar with a statistically significant finding suggesting that non-
Hispanic whites were at the greatest risk for AMD. The multivariate results did not 
appear to be modified by the other covariates. 
Smoking and AMD 
In this study, I found smoking to be statistically significantly associated to the 
presence of AMD in the bivariate model, but not the multivariate model. In the bivariate 




compared to non-smokers. The odds ratio was .809 (95% CI: .569 to 1.151) for current 
smokers when compared to non-smokers. These results suggested that past smokers were 
1.58 times more likely to have AMD than non-smokers and current smokers are 1.23 
times less likely to have AMD than non-smokers. The confidence interval for the past 
smokers comparison did not include 1 suggesting that smoking was predictive of AMD. 
The bivariate results confirmed previous findings from the AREDS study suggesting 
smoking is a risk factor for AMD. However, findings in this study indicating past 
smokers were at higher risk for having AMD than current smokers differed from the 
findings of Chew and colleagues (2014) and Tomany and colleagues (2004) of the 
inverse where current smokers were at higher risk than past smokers of having AMD.  
In the multivariate model, the p value for smoking comparison to AMD went up 
to .283 (losing statistical significance) indicating the other variables in the model had a 
modifying effect on smoking. Age was most likely the variable that had the most effect 
on the multivariate model as I found age to be the strongest predictor of AMD. The 
pseudo R2 tests showed the multivariate model as the strongest with a range from .043 to 
.110. Age had the next highest values with a range from .040 to .104 and was found to 
have the highest pseudo R2 values of all of the individual models. These findings indicate 
that age was the most predictive of AMD and provided the strongest model behind the 
multivariate model potentially modifying the other variables. 
The life course epidemiology model was utilized as the theoretical framework for 
this study. I found a history of past smoking to be associated with development of AMD. 




development was represented in this comparison. The smoking variable demonstrated 
how the life course theory plays a role in studying disease development. Age as a 
modifying factor played a role in how the smoking variable had a potential to change in 
the multivariate model further demonstrating how other factors have modifying effects on 
one another. 
Limitations of the Study 
Limitations of the study include: not understanding the source of vitamin D (food, 
supplements, sun exposure), self-reports of data, small number of participants that have 
AMD compared to non-AMD, small percentage of participants with low vitamin D and 
even smaller percentage with extremely low (deficient) vitamin D, and differing vitamin 
D level measurements between 2-year datasets. Understanding the source of vitamin D 
would allow for better understanding of the current versus past state of vitamin D status. 
For example, if vitamin D levels were attributed from use of supplements, then perhaps 
vitamin D level would have recently changed thereby making it difficult to ascertain an 
association to the affect of presence or absence of disease. 
Individual participant bias for the self-reported data variables included smoking 
and diabetes. Smokers may have provided answers they felt were more socially 
acceptable and therefore contributed to bias in the study. In addition, when answering 
specifics about smoking habits, memory recall may not have been accurate also 
contributing to bias. A more accurate data collection method for diabetes status would 
have been to collect medical records for participants in the study rather than to collect 




because it contributed to potential bias. AMD by definition is a disease of older 
individuals and increases potential recall bias due to worse memory recall in the aging 
population.  
Race as a covariate is straightforward and should not have contributed to bias that 
influenced outcomes. The method of data collection for both the independent variable 
(vitamin D level) and dependent variable (stage of AMD) were collected in a manner that 
minimized recall bias. Those methods included vitamin D testing done in a lab and 
reading of retinal images that were performed by masked readers (NHANES, 2015). 
However, the lab method for vitamin D measurement changed from the 2005–2006 and 
2007–2008 data collection years (as discussed in more detail in Chapter 3), which 
presented a potential limitation through measurement bias. In addition, source of vitamin 
D from food, supplements, or amount of sun exposure was not estimated, which may 
have influenced the results.  
Recommendations 
A recommendation based on the findings from this study is to attempt to better 
understand the diabetes to AMD association. Future researchers should consider using 
physician medical records with diagnosis information as an alternative approach to 
evaluate this association further. Of all of the variables studied here, diabetes is the least 
studied in terms of association to AMD. Age, smoking status, and ethnicity are well 
established at this point. The body of literature on vitamin D association to AMD is still 
growing, but it appears that the evidence remains unclear. The data from this study and 




continue with considerable thought on how to strengthen studies with large AMD 
populations. This study did not evaluate the association broken down by early and late 
AMD and further research with large enough numbers to evaluate both will be important. 
The number of NVAMD (late AMD) individuals has been small in the previous studies 
and provides an opportunity for further exploration. Perhaps finding a population to study 
with large numbers of individuals in higher age categories that are more likely to have 
advanced disease would be beneficial. 
Implications for Social Change 
The findings from this study could be used for positive social change by 
encouraging medical and public health agencies to target screening programs at high-risk 
age, smoking, and race groups. There remains to be conflicting data in the literature. This 
study adds to the body of literature suggesting that higher levels of vitamin D are not 
necessarily beneficial. There has been an increase in the community recommending more 
focus on and testing of vitamin D levels. The associated emphasis has been on 
maintaining increased vitamin D levels for health benefits. Perhaps it is not the case when 
evaluating AMD risk and vitamin D is not as closely associated with AMD as the 
thinking was trending toward. However, this study does confirm previous findings of age, 
race, and smoking status association to AMD. Health care professionals can use this 
information to target screening for AMD among at-risk groups. Perhaps AMD screenings 
among older, white individuals would be beneficial. Since an association was also not 
found between diabetes and AMD, perhaps more research needs to be conducted on this 





This study attempts to better understand the association between vitamin D and 
AMD in a large weighted sample from the publicly available NHANES dataset that is 
representative of the U.S. population. The study fails to find an association between 
vitamin D and AMD. Covariates that are included in the analysis are diabetes, age, race, 
and smoking status. Age is strongly predictive of AMD and has an affect on the 
multivariate model. 
The findings from this study conducted from a large population sample 
representative of the U.S. population adds to the literature on the topic of vitamin D 
association to AMD. The results of this study do not support an inverse association of 
vitamin D to AMD and fails to support a specific role for vitamin D in AMD. It is still 
unknown whether vitamin D supplements, a diet rich in vitamin D, or safe exposure to 
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